dpf-2 Antibody

What is DPF2 and what cellular functions does it regulate?

DPF2 (D4, zinc and double PHD fingers family 2), also known as BAF45D, is a 391 amino acid protein with a calculated molecular weight of 44 kDa (observed at 44-50 kDa in experiments) that functions as a transcription regulator . DPF2 serves as an adaptor protein linking the noncanonical NF-κB complex (RelB/p52) with the SWI/SNF chromatin-remodeling complex . This interaction is crucial for activating the noncanonical NF-κB pathway, which plays a significant role in regulating innate immunity. Research has demonstrated that DPF2 negatively regulates type I interferon induction through attenuated recruitment of canonical NF-κB at the IFN-β promoter .

What applications have been validated for DPF2 antibodies?

DPF2 antibodies have been validated for multiple experimental applications with specific cellular and tissue systems:

These applications have been documented in multiple publications, supporting their reliability in research settings .

How should researchers optimize antigen retrieval for DPF2 immunohistochemistry?

For optimal DPF2 detection in tissue sections, researchers should implement a systematic approach to antigen retrieval. Primary experiments should use TE buffer at pH 9.0, which has shown superior results for DPF2 epitope recovery . If results are suboptimal, alternative antigen retrieval with citrate buffer at pH 6.0 can be tested as a secondary approach. The antigen retrieval process should include careful temperature monitoring (95-98°C) and consistent timing (15-20 minutes) to ensure reproducibility. Following retrieval, tissue sections should be gradually cooled to room temperature before proceeding with blocking and primary antibody incubation. Researchers should also incorporate both positive controls (tissues known to express DPF2) and negative controls (omission of primary antibody) to validate staining specificity.

What are the critical considerations for knockdown studies involving DPF2?

When designing DPF2 knockdown experiments, researchers should address several methodological considerations:

• siRNA selection: Use pools of four siRNAs against DPF2 to minimize off-target effects, as demonstrated in published research

• Knockdown verification: Validate knockdown efficiency at both mRNA level (qRT-PCR) and protein level (Western blot)

• Timing: DPF2 knockdown effects on viral replication are observable at 4-8 hours post-infection (hpi), corresponding to a single infection cycle

• Controls: Include scrambled siRNA as negative control to account for non-specific effects of transfection

• Functional readouts: Plan to measure multiple parameters including:

  • Viral protein expression

  • Viral RNA levels

  • IFN-β mRNA expression

  • STAT1 phosphorylation status

  • Proinflammatory cytokine/chemokine expression (IP-10, IL-8, IL-6)

  • Antiviral gene expression (MxA, ISG56)

Significant changes in immune response markers have been documented following DPF2 knockdown in influenza virus-infected cells, with elevated expression of IFN-β, phosphorylated STAT1, and multiple cytokines .

How can DPF2 antibodies be used to investigate virus-host interactions?

DPF2 antibodies can be strategically employed to investigate the role of DPF2 in virus-host interactions through several complementary approaches:

• Subcellular localization studies: Use immunofluorescence to track DPF2 translocation during viral infection. Research has shown that DPF2 specifically translocates from the cytoplasm to the nucleus in influenza virus-infected cells .

• Co-immunoprecipitation: Apply IP with DPF2 antibodies (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate) to identify virus-induced protein-protein interactions, particularly with components of the noncanonical NF-κB pathway.

• Chromatin immunoprecipitation (ChIP): Utilize DPF2 antibodies to investigate recruitment to specific promoter regions (e.g., IFN-β) during viral infection.

• Temporal expression analysis: Monitor DPF2 expression levels throughout viral infection cycle using Western blot, with standardized loading controls.

• Comparison across viral systems: Research indicates that DPF2 is specifically involved in influenza A and B virus replication but not HCV or Ebola virus replication , suggesting targeted research applications.

What methodologies can resolve conflicting DPF2 expression data across different experimental systems?

When researchers encounter conflicting DPF2 expression data across different systems, a systematic troubleshooting approach should be implemented:

• Antibody validation: Confirm antibody specificity using knockdown/knockout controls. The full DPF2 protein is 391 amino acids with a calculated molecular weight of 44 kDa, but the observed range is 44-50 kDa .

• Sample preparation consistency: Standardize cell lysis buffers and protein extraction methods. For DPF2, complete solubilization is critical.

• Loading control normalization: Use multiple housekeeping proteins as loading controls (e.g., GAPDH, β-actin, tubulin) to account for potential regulation of individual controls.

• Cell type-specific expression profiling: Systematically compare expression across validated cell lines (Jurkat, HeLa, Y79, HepG2, K-562) to identify cell type-specific regulation .

• Post-translational modification analysis: Investigate phosphorylation states of DPF2 that may affect antibody recognition or protein function, particularly in relation to the noncanonical NF-κB pathway activation .

• Protein turnover evaluation: Measure DPF2 protein half-life across experimental systems using cycloheximide chase or pulse-chase experiments.

• Middle-up mass spectrometry: For definitive protein identification, consider middle-up liquid chromatography-quadrupole time-of-flight mass spectrometry to confirm protein identity and detect potential modifications or isoforms .

How should researchers troubleshoot non-specific binding in DPF2 Western blots?

When encountering non-specific binding in DPF2 Western blots, researchers should systematically address potential sources of error:

• Optimization of antibody dilution: Test a dilution series within the recommended range (1:1000-1:8000) to identify optimal signal-to-noise ratio.

• Blocking optimization: Evaluate different blocking agents (5% non-fat milk, 5% BSA, commercial blockers) for 1-2 hours at room temperature.

• Washing stringency adjustment: Increase TBST wash steps (5-6 times, 5-10 minutes each) to remove weakly bound antibodies.

• Sample preparation refinement: Ensure complete protein denaturation by:

  • Heating samples at 95°C for 5 minutes

  • Using fresh reducing agents

  • Including protease inhibitors during lysate preparation

• Membrane optimization: Compare PVDF and nitrocellulose membranes for optimal DPF2 detection.

• Positive control inclusion: Include validated DPF2-expressing cells (Jurkat, HeLa, Y79, HepG2, K-562) as positive controls.

• Negative control validation: Include samples with confirmed DPF2 knockdown to identify the specific DPF2 band.

• Antibody validation: Consider testing alternative DPF2 antibodies targeting different epitopes to confirm specificity.

What strategies can improve detection sensitivity for low-abundance DPF2 in immunofluorescence studies?

For detecting low-abundance DPF2 protein by immunofluorescence, researchers should implement the following methodological improvements:

• Fixation optimization: Compare 4% paraformaldehyde (10-15 minutes) with methanol fixation (-20°C, 10 minutes) to determine optimal epitope preservation.

• Permeabilization adjustment: Test graduated concentrations of Triton X-100 (0.1-0.5%) or saponin (0.1-0.3%) to optimize cellular access while preserving structure.

• Signal amplification: Implement tyramide signal amplification (TSA) to enhance detection sensitivity by 10-100 fold while maintaining specificity.

• Antibody concentration adjustment: Use the higher end of the recommended dilution range (1:10-1:20) for primary antibody.

• Extended incubation: Increase primary antibody incubation to overnight at 4°C with gentle agitation.

• Detection system selection: Compare fluorophore-conjugated secondary antibodies with different excitation/emission properties to minimize autofluorescence interference.

• Advanced microscopy techniques: Utilize confocal microscopy with appropriate negative controls to distinguish specific signals from background.

• Image acquisition optimization: Implement multiple exposure settings and z-stack acquisition to capture the complete signal range.

• Quantitative analysis: Apply automated image analysis software to quantify signal intensity across multiple fields and experimental conditions.

How should researchers interpret changes in DPF2 expression during immune activation?

The interpretation of DPF2 expression changes during immune activation requires careful consideration of multiple parameters:

• Baseline expression assessment: Establish normal DPF2 expression levels in resting cells before immune stimulation. DPF2 is detectable in multiple cell types including Jurkat, HeLa, Y79, HepG2, and K-562 cells .

• Temporal dynamics: Evaluate expression changes at multiple time points (early: 0-4 hours; intermediate: 4-12 hours; late: 12-24+ hours) to capture transient regulatory events.

• Subcellular localization shifts: Monitor potential translocation between cytoplasm and nucleus during immune activation, as DPF2 has been shown to translocate from cytoplasm to nucleus during viral infection .

• Correlation with NF-κB pathway activity: Measure canonical and noncanonical NF-κB pathway markers (RelB/p52 complex formation, p100 processing) in parallel with DPF2 expression changes.

• Functional pathway correlation: Assess relationship between DPF2 expression levels and downstream IFN-β expression, which is negatively regulated by DPF2 .

• Statistical validation: Apply appropriate statistical tests across biological replicates (minimum n=3) to validate significance of observed changes.

• Causal verification: Confirm causality through gain-of-function and loss-of-function experiments (overexpression and knockdown) to establish direct relationship between DPF2 levels and immune responses.

What is the significance of DPF2's role in viral pathogenesis and how can this be experimentally validated?

DPF2's role in viral pathogenesis, particularly for influenza virus, represents an important area for therapeutic exploration, which can be experimentally validated through multiple approaches:

• Infection kinetics in DPF2-modulated cells: Research has demonstrated that DPF2 knockdown results in a two-log reduction in influenza virus production in multiple-cycle growth kinetics assays . This can be validated using plaque assays or TCID50 measurements.

• Virus-specific activity profiling: Experimental evidence indicates that DPF2 is specifically required for influenza A and B virus replication but not for HCV or Ebola virus , suggesting a virus-specific mechanism that should be investigated through comparative studies.

• Mechanistic pathway analysis: Systematically examine:

  • IFN-β mRNA expression (elevated in DPF2 knockdown cells)

  • STAT1 phosphorylation status (increased in DPF2 knockdown cells)

  • Proinflammatory cytokine/chemokine expression (IP-10, IL-8, IL-6)

  • Antiviral gene expression (MxA, ISG56)

• Direct binding studies: Investigate potential direct interactions between DPF2 and viral components using techniques such as:

  • Co-immunoprecipitation

  • Proximity ligation assay

  • FRET or BiFC for live-cell interaction analysis

• Structure-function analysis: Map functional domains of DPF2 critical for viral replication support through deletion constructs and point mutations.

• In vivo validation: Extend findings to animal models using conditional knockout approaches to validate the physiological relevance of DPF2 in viral pathogenesis and potential therapeutic targeting.

• Therapeutic targeting evaluation: Assess whether small molecule inhibitors or peptide-based approaches targeting DPF2 could serve as potential antivirals, as DPF2 has been identified as "one of six genes for which knockdown significantly decreased the infectivity of influenza virus" .